Russell Frank Company’s Amicus Therapeutics FOLD Stock Holding History

Russell Frank Company’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-93,774	Closed	-$1.31M	–	3000
2015 Q3	$1.31M	Sell	93,774 -66,653	-42%	-$1.05M	﹤0.01%	2082
2015 Q2	$2.27M	Sell	160,427 -29,112	-15%	-$350K	﹤0.01%	1894
2015 Q1	$2.06M	Sell	189,539 -101,340	-35%	-$893K	﹤0.01%	1757
2014 Q4	$2.39M	Buy	290,879 +35,137	+14%	+$241K	﹤0.01%	1681
2014 Q3	$1.52M	Buy	+255,742	New	+$1.34M	﹤0.01%	1872
2013 Q4	–	Sell	-171	Closed	–	–	2883
2013 Q3	$0	Sell	171 -23	-12%	-$58	﹤0.01%	3462
2013 Q2	$0	Buy	+194	New	+$596	﹤0.01%	3356

Other funds holding FOLD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Russell Frank Company's FOLD Position: Q4 2015 in Review

Russell Frank Company sold out of Amicus Therapeutics (FOLD) in Q4 2015, closing a stake of 93,774 shares — an estimated $1.31M sold.

Russell Frank Company first reported a position in FOLD in Q2 2013 and held it in 7 quarters. The position peaked at $2.39M in Q4 2014. 139 funds tracked by Wall St. Rank hold FOLD as of Q4 2015.

Russell Frank Company reported no remaining Amicus Therapeutics position as of Q4 2015 after selling out during the quarter.
Russell Frank Company sold 93,774 Amicus Therapeutics shares in Q4 2015, an estimated $1.31M.
Russell Frank Company first reported a position in Amicus Therapeutics in Q2 2013 and held it in 7 quarters.
Russell Frank Company's Amicus Therapeutics position peaked at $2.39M in Q4 2014.
139 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2015.

Based on Russell Frank Company's 13F filing for Q4 2015, filed 27 Jan 2016.